Skip to main content
OpenTrials
Completed

NCT Number: NCT01385800

ToleroMune Grass Exposure Unit Study

Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass pollen. ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of grass allergy.

This study will look at the efficacy, safety and tolerability of three doses of ToleroMune Grass in grass allergic subjects following challenge with with grass in an Environmental Exposure Unit (EEU).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Kingston General Hospital

Kingston, Ontario, K7L 2V7, Canada

About this study

This study is designed as a randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of ToleroMune Grass in grass allergic subjects with allergic rhinoconjunctivitis. The efficacy of ToleroMune Grass will be explored in subjects using an EEU (Environmental Exposure Unit).

The study will consist of 3 study periods. In Period 1, Screening will be performed up to a maximum of 16 weeks before randomisation and may consist of one or two visits to the clinic, at the Investigator's discretion. Baseline Challenge will consist of 4 visits to the EEU at least 3 days before randomisation.

In Period 2, subjects in each cohort complying with the inclusion/exclusion criteria will be randomised to one of four groups and will receive treatment every 2 weeks (±2 days) for 14 weeks.

In Period 3, Post Treatment Challenge will consist of 4 visits to the EEU about 25 weeks after the first administration in the treatment period and assessments will be performed identical to those at the baseline challenge. Follow-up will be conducted 3-10 days after PTC.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, aged 18-65 years.
  • Minimum 2-year documented history of rhinoconjunctivitis on exposure to grass.
  • Positive skin prick test to grass allergen.
  • Minimum qualifying rhinoconjunctivitis symptom scores

Exclusion criteria

  • History of asthma.
  • A history of anaphylaxis to grassallergen.
  • Subjects with an FEV1 <80% of predicted.
  • Subjects who cannot tolerate baseline challenge in the EEU.
  • Subjects for whom administration of epinephrine is contra-indicated (e.g. subjects with acute or chronic symptomatic coronary heart disease or severe hypertension).
  • A history of severe drug allergy, severe angioedema or anaphylactic reaction to food.
  • A history of any significant disease or disorder (e.g. cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, neoplastic/malignant, psychiatric, major physical impairment).

Treatment and study plan

ToleroMune Grass

Biological

Intradermal injection 1 x 8 administrations 2 weeks apart

Placebo

Biological

Intradermal injection 1 x 8 administrations 2 weeks apart

Primary outcomes

  1. Total Rhinoconjunctivitis Symptom Score

    Time frame: Upto 25 weeks

Secondary outcomes

  1. Symptom scores for nasal and non nasal symptoms

    Time frame: Upto 25 weeks

  2. Skin prick testing

    Time frame: Upto 25 weeks

  3. Peak Nasal Inspiratory Flow

    Time frame: Up to 25 weeks

  4. Grass specific IgA

    Time frame: Upto 26 weeks

  5. Grass specific IgE

    Time frame: Upto 26 weeks

  6. Grass specific IgG4

    Time frame: Up to 26 weeks

  7. Adverse Events

    Time frame: Up tp 26 weeks

Sponsors and collaborators

Lead sponsor

Circassia Limited

Industry

Collaborators

  • Adiga Life Sciences, Inc.
  • Pharm-Olam International

Registry information

Official study title

A Double-blind, Randomised, Placebo-controlled Study to Evaluate Three Doses of ToleroMune Grass in Grass Allergic Subjects Following Challenge With Grass Allergen in an Environmental Exposure Unit

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Jun 30, 2011
Registry last updated
Aug 15, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.